Clovis gains on 4Q increase in Rubraca sales

Clovis Oncology Inc. (NASDAQ:CLVS) reported $30.4 million in 4Q18 revenue, all from U.S. sales of Rubraca rucaparib, up 78% from $17 million in 4Q17 and beating the consensus estimate of $27 million. For the year, Rubraca generated $95.4 million in revenue, a 72% increase from $55.5 million in 2017.

Clovis gained $3.43 (13%) to $29.48 on Feb. 27, when it announced the news...